公开(公告)号：US12201679B2

公开(公告)日：2025-01-21

申请号：US16841635

申请日：2020-04-06

Applicant: Institute for Systems Biology

Inventor： James R. Heath ,  Matthew N. Idso ,  Mario Arrieta-Ortiz ,  Ajay Akhade

IPC: A61K38/08 ,  A61K39/085 ,  A61K39/108 ,  A61K47/64 ,  C07K7/06 ,  G01N33/68

Abstract: Disclosed are compounds, compositions, and methods relating to epitope-targeted immunostimulants (EPIs), which comprise a synthetic peptide ligand and an antibody-recruiting moiety. The peptide ligand binds an epitope on a target and the antibody-recruiting moiety recruits antibodies to the target when the EPI is bound to the epitope on the target. Also disclosed are compositions comprising any of the disclosed EPIs. Also disclosed are methods of stimulating an immune reaction to a microorganism or other pathogen in a subject where an EPI is administered to the subject. Also disclosed are methods of identifying the peptide ligand by using multi-omic analysis.

公开(公告)号：US20240191209A1

公开(公告)日：2024-06-13

申请号：US18484993

申请日：2023-10-11

Applicant: Universidade do Porto - Reitoria

Inventor： Paula Maria DAS NEVES FERREIRA DA SILVA ,  Pedro Jorge Fonseca MADUREIRA

IPC: C12N9/02 ,  A01K67/0275 ,  A61K39/00 ,  A61K39/085 ,  A61K39/09 ,  A61K39/095 ,  A61K39/104 ,  A61K39/108 ,  C07K16/40

CPC classification number: C12N9/0008 ,  A01K67/0275 ,  A61K39/0258 ,  A61K39/0266 ,  A61K39/085 ,  A61K39/092 ,  A61K39/095 ,  A61K39/104 ,  C07K16/40 ,  C12Y102/01012 ,  A01K2217/00 ,  A61K2039/505 ,  A61K2039/55 ,  A61K2039/57 ,  C07K2317/76

Abstract: The invention provides peptides derived from a ubiquitous protein, and nucleic acids encoding such peptides. The invention extends to various uses of these peptides and nucleic acids, for example, as antigens for use in vaccines per se and in the generation of antibodies for use in therapeutic drugs for the prevention, amelioration or treatment of infections caused by sepsis-inducing bacteria. The invention particularly benefits immunocompromised hosts such as neonates, babies, children, women of fertile age, pregnant women, foetuses, the elderly and diabetics.

公开(公告)号：US20240190927A1

公开(公告)日：2024-06-13

申请号：US18583180

申请日：2024-02-21

Applicant: THE UNIVERSITY OF CHICAGO

Inventor： Olaf SCHNEEWIND ,  Alice G. CHENG ,  Dominique M. MISSIAKAS ,  Hwan Keun Kim

IPC: C07K14/31 ,  A61K39/00 ,  A61K39/085 ,  C07K16/12

CPC classification number: C07K14/31 ,  A61K39/085 ,  C07K16/1271 ,  A61K2039/57

Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.

公开(公告)号：US20240132552A1

公开(公告)日：2024-04-25

申请号：US18479501

申请日：2023-10-01

Applicant: Evaxion Biotech A/S

Inventor： Niels Iversen Møller ,  Andreas Holm Mattson

IPC: C07K14/31 ,  A61K39/085 ,  C07K16/12 ,  C12Q1/689 ,  G01N33/569

CPC classification number: C07K14/31 ,  A61K39/085 ,  C07K16/1271 ,  C12Q1/689 ,  G01N33/56938 ,  A61K2039/55505 ,  G01N2333/31 ,  G01N2500/04

Abstract: The present invention relates to proteins and nucleic acids derived from Staphylococcus aureus as well as therapeutic and diagnostic uses of the proteins and nucleic acids.

公开(公告)号：US20240091331A1

公开(公告)日：2024-03-21

申请号：US18388952

申请日：2023-11-13

Applicant: Longhorn Vaccines and Diagnostics, LLC

Inventor： Gerald W. Fischer ,  Clara J. Sei ,  Jeffrey D. Fischer

IPC: A61K39/04 ,  A61K39/085 ,  A61P31/06 ,  C07K14/31 ,  C07K14/35

CPC classification number: A61K39/04 ,  A61K39/085 ,  A61P31/06 ,  C07K14/31 ,  C07K14/35 ,  A61K2039/55566

Abstract: The invention relates to compositions and peptides or peptide sequences that induce an immune response in an animal or a mammal that is protective against infection by one or more pathogens. In addition, the invention relates to immunogenic composition and vaccines comprising compositions and peptide sequences and to method for treating and preventing an infection in animals and mammals such as humans and antibodies.

公开(公告)号：US20240050546A1

公开(公告)日：2024-02-15

申请号：US18028477

申请日：2021-09-28

Applicant: JANSSEN PHARMACEUTICALS, INC. ,  NEW YORK UNIVERSITY

Inventor： Brian MORROW ,  Sergey KONSTANTINOV ,  Jeroen GEURTSEN ,  Jinquan LUO ,  Sandeep SOMANI ,  Peter T. BUCKLEY ,  Victor J. TORRES

IPC: A61K39/085 ,  C07K14/31 ,  A61P31/04

CPC classification number: A61K39/085 ,  C07K14/31 ,  A61P31/04

Abstract: The present disclosure relates to Staphylococcus aureus leukocidin A (LukA) and leukocidin B (LukB) variant polypeptides, and polynucleotides encoding the LukA, LukB and LukAB variant polypeptides. The present disclosure further relates to vaccine compositions comprising these LukA and LukB variants, and methods of generating an immune response against Staphylococcus aureus in a subject.

公开(公告)号：US20240042002A1

公开(公告)日：2024-02-08

申请号：US17789451

申请日：2020-12-31

Applicant: ANTAGONIS ,  UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Inventor： Cassie RIBEIRO ,  Martin ROTTMAN ,  Jean-Louis GAILLARD

IPC: A61K39/085 ,  A61K39/40 ,  A61P31/04 ,  G01N33/569 ,  C12Q1/18

CPC classification number: A61K39/085 ,  A61K39/40 ,  A61P31/04 ,  G01N33/56938 ,  C12Q1/18 ,  G01N2333/31 ,  G01N2469/10

Abstract: The present invention relates to an immunogenic composition comprising at least one Staphylococcus aureus antigen, wherein said antigen is a polypeptide having at least 80% identity with the SdrH-like polypeptide of SEQ ID NO: 8, Nuc of SEQ ID
NO: 4, or LukG of SEQ ID NO: 12, an immunotherapeutic composition comprising a polyclonal antibody which selectively binds to at least one of said antigens, and an in vitro method of identifying an antigen conferring protection against disease caused by S. aureus in a subject.

公开(公告)号：US11819544B2

公开(公告)日：2023-11-21

申请号：US16954337

申请日：2018-12-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Amirreza Faridmoayer ,  Sabina Marietta Gerber ,  Stefan Jochen Kemmler

IPC: A61K39/085 ,  A61K47/64 ,  A61K39/00 ,  C07K14/31

CPC classification number: A61K39/085 ,  A61K47/646 ,  C07K14/31 ,  A61K2039/6068

Abstract: The present invention discloses modified Staphylococcus aureus ClfA proteins that contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified ClfA protein and an antigen (for example a Staphylococcus aureus saccharide antigen), wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the modified ClfA protein.

公开(公告)号：US11773157B2

公开(公告)日：2023-10-03

申请号：US17659466

申请日：2022-04-15

Applicant: XBiotech Inc.

Inventor： John Simard

IPC: A61K39/40 ,  C07K16/12 ,  A61K38/14 ,  A61K38/12 ,  A61K39/00 ,  A61K39/085

CPC classification number: C07K16/1271 ,  A61K38/12 ,  A61K38/14 ,  A61K39/40 ,  A61K39/085 ,  A61K2039/505 ,  A61K2300/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Antibodies having Fab regions that specifically bind to Staphylococcus aureus protein A are capable of mediating opsinization of Staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein A. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing Staphylococcus aureus infections.

公开(公告)号：US11723971B2

公开(公告)日：2023-08-15

申请号：US16703770

申请日：2019-12-04

Applicant: JN Biosciences, LLC ,  Abmuno Therapeutics, LLC

Inventor： J. Yun Tso ,  Naoya Tsurushita ,  Omar Duramad

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/085 ,  A61K39/08 ,  A61K39/39 ,  C07K16/30 ,  A61K39/00

CPC classification number: A61K39/39541 ,  A61K39/08 ,  A61K39/085 ,  A61K39/39 ,  A61K39/3955 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2878 ,  C07K16/2896 ,  C07K16/3061 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2121/00 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/70 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  Y02A50/30

Abstract: The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.